688526.SH
Wuhan Keqian Biology Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 11.69
+1.56%Oct 30, 2026, 10:30 UTC
Kofun Biotech reported first-nine-month 2026 revenue of 575 million yuan, down 22.09% year over year, and net profit attributable to shareholders of 146 million yuan, down 56.76%.
Source:Oct 30, 2026, 10:30 UTC
Kofun Biotech reported third-quarter 2026 revenue of 201 million yuan, down 19.76% year over year, and net profit attributable to shareholders of 30.3356 million yuan, down 74.27%.
Source:Sep 14, 2026, 08:11 UTC
Kequan Biotechnology received approval from China's Ministry of Agriculture and Rural Affairs for its trivalent inactivated vaccine against feline rhinotracheitis, calicivirus disease and panleukopenia, obtaining a New Veterinary Drug Registration Certificate with a 3-year monitoring period.
Aug 26, 2026, 11:40 UTC
Keqian Biology announced its first-half 2026 results: net profit attributable to shareholders was 116 million yuan, down 47.37% year-on-year.
Source:Aug 24, 2026, 10:15 UTC
Keqian Biology received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its avian adenovirus (group I, type 4) inactivated vaccine (HB-2 strain) to be registered as a new veterinary drug, and obtained the new veterinary drug registration certificate.